AN2 Therapeutics Inc.
ANTX | NASDAQ
$4.45
-$0.08 (-1.77%)
Nov 2, 2026, 9:58 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -38.81M | -37.12M | -38.11M | -37.39M | -41.37M | -50.03M | -56.79M | -67.01M | -71.17M | -71.89M | -69.64M | -63.3M | -56.89M | -50.62M | -42.26M | -37.38M | -32.54M | -27.21M | -21.57M | -13.98M | -7.05M | -2.05M |
Interest Income | 2.54M | 2.57M | 2.93M | 2.33M | 2.91M | 3.6M | 4.39M | 4.39M | 3.12M | 1.68M | n/a | 630K | 1.1M | 1.32M | 1.35M | 748K | 307K | 94K | 69K | 42K | 17K | 2K |
Pretax Income | -36.28M | -34.55M | -35.17M | -33.99M | -37.38M | -45.35M | -51.32M | -60.7M | -64.66M | -66.03M | -64.73M | -59.68M | -54.31M | -48.62M | -40.96M | -36.66M | -32.26M | -27.15M | -21.54M | -14M | -7.06M | -2.05M |
Net Income | -36.28M | -34.55M | -35.17M | -33.99M | -37.38M | -45.35M | -51.32M | -60.7M | -64.66M | -66.03M | -64.73M | -59.68M | -54.31M | -48.62M | -40.96M | -36.66M | -32.26M | -27.15M | -21.54M | -14M | -7.06M | -2.05M |
Selling & General & Admin | 12.17M | 13.3M | 13.34M | 14.11M | 14.56M | 14.27M | 14.07M | 14.75M | 15.02M | 14.35M | 14.76M | 14.59M | 14.18M | 14.76M | 12.75M | 10.81M | 9.05M | 6.32M | 4.67M | 2.89M | 1.3M | 401K |
Research & Development | 26.64M | 23.82M | 24.77M | 23.29M | 24.57M | 33.52M | 40.49M | 50.01M | 56.15M | 57.54M | 54.87M | 48.7M | 42.7M | 35.86M | 29.51M | 26.57M | 23.49M | 20.89M | 16.91M | 11.09M | 5.75M | 1.65M |
Other Expenses | n/a | n/a | n/a | -9K | 2.23M | 2.23M | 2.23M | 2.24M | n/a | n/a | 0 | 0 | 0 | 0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 38.81M | 37.12M | 38.11M | 37.39M | 41.37M | 50.03M | 56.79M | 67.01M | 71.17M | 71.89M | 69.64M | 63.3M | 56.89M | 50.62M | 42.26M | 37.38M | 32.54M | 27.21M | 21.57M | 13.98M | 7.05M | 2.05M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.81M | 37.12M | 38.11M | 37.39M | 41.37M | 50.03M | 56.79M | 67.01M | 71.17M | 71.89M | 69.64M | 63.3M | 56.89M | 50.62M | 42.26M | 37.38M | 32.54M | 27.21M | 21.57M | 13.98M | 7.05M | 2.05M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 44.76M | 34.06M | 30.22M | 30.28M | 30.17M | 30.05M | 29.88M | 29.84M | 29.83M | 29.76M | 29.74M | 25.65M | 19.5M | 19.39M | 19.4M | 19.35M | 19.26M | 19M | 18.14M | 14.05M | 14.05M | 14.05M |
Shares Outstanding (Diluted) | 44.76M | 34.06M | 30.22M | 30.28M | 30.17M | 30.05M | 29.88M | 29.84M | 29.83M | 29.76M | 29.74M | 25.65M | 19.5M | 19.39M | 19.4M | 19.35M | 19.26M | 19M | 18.14M | 14.05M | 14.05M | 14.05M |
EPS (Basic) | -1.07 | -1.10 | -1.16 | -1.12 | -1.24 | -1.51 | -1.72 | -2.04 | -2.26 | -2.59 | -2.78 | -2.87 | -2.78 | -2.49 | -2.14 | -1.90 | -1.97 | -1.94 | -1.74 | -1.32 | -0.69 | -0.20 |
EPS (Diluted) | -1.07 | -1.10 | -1.16 | -1.12 | -1.24 | -1.51 | -1.72 | -2.04 | -2.26 | -2.59 | -2.78 | -2.87 | -2.78 | -2.49 | -2.14 | -1.90 | -1.97 | -1.94 | -1.74 | -1.32 | -0.69 | -0.20 |
EBITDA | -37.57M | -35.85M | -36.47M | -26.46M | -28.88M | -11.45M | -17.42M | -33.9M | -20.66M | -47.43M | -30.1M | -25.46M | -38.27M | -32.59M | -40.96M | -29.07M | -24.67M | -19.56M | -13.95M | -14M | -7.06M | -2.05M |
EBIT | -37.57M | -35.85M | -36.47M | -35.07M | -37.49M | -45.46M | -51.43M | -59.72M | -64.66M | -66.03M | -64.73M | -59.68M | -54.31M | -48.62M | -40.96M | -36.66M | -32.26M | -27.15M | -21.55M | -14M | -7.06M | -2.05M |
Depreciation & Amortization | n/a | n/a | n/a | 8.61M | 8.61M | 34.02M | 34.02M | 25.82M | 44M | 18.59M | 34.63M | 34.22M | 16.04M | 16.04M | n/a | 7.59M | 7.59M | 7.59M | 7.59M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ANTX